Foresite Capital

Foresite Capital is a multi-stage investment firm specializing in healthcare and life sciences, managing approximately $2 billion in assets. The firm employs a rigorous, data-driven approach to investment analysis and collaborates closely with its portfolio companies, offering a diverse team of scientists, engineers, analysts, and clinicians. This collaborative model enables Foresite Capital to understand the distinct business models within the healthcare sector. The firm focuses on addressing significant unmet clinical needs by investing in promising healthcare and life sciences enterprises across various stages of development. Additionally, Foresite Capital prioritizes companies that leverage data science and machine intelligence to innovate within the healthcare landscape. The firm is headquartered in San Francisco, with an additional office in New York.

Vikram Bajaj

Managing Director & Board Member

Shannon Bergstedt

Principal

Matt Buten

Managing Director and Partner

Hyung Chun

Partner

Shoman Kasbekar

Principal

Rhonda Kaufman

Director

Richard Lau

Partner

Alisa Mall

MD

Dorothy Margolskee

Managing Director

Stephen Peterson

Managing Director

Hemaka Rajapakse

Managing Director

Jonathan Robbins

Investor

Michael Rome Ph.D

Managing Director

Dennis D. Ryan

CFO and Managing Director

Damien Soghoian

Director

Jim Tananbaum

Founder and CEO

Tony Wiemelt

Managing Director

Cindy Xiong

Investor

Past deals in TMT

ImmPACT Bio

Series B in 2022
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Mythic Therapeutics

Series B in 2021
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. Mythic Therapeutics was founded in 2017 and is headquartered in Waltham, MA, USA.

Tango Therapeutics

Post in 2021
Tango Therapeutics, Inc., a biotechnology company, develops cancer drugs based on synthetic lethality. The company uses the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. It focuses counteracting tumor suppressor gene loss; reversing the ability of cancer cells to evade the immune system; and identifying novel combinations that are more effective than single agent therapy. Tango Therapeutics, Inc. was formerly known as Cancer Combos NewCo, Inc. The company was incorporated in 2014 and is based in Cambridge, Massachusetts.

Tempest Therapeutics

Series B in 2018
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Tarsa Therapeutics

Series B in 2014
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.

Tarsa Therapeutics

Series B in 2012
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.